Another study found AR inhibitors enzalutamide and bicalutamide upregulated CCL2 via STAT3 in PCa cells, leading them to propose the use of CCL2/CCR2 or STAT3 inhibitors in combination with AR inhibitors to block the pro-tumoral effects of ADT-induced CCL2 (255). This evidence concerns the gene STAT3 and posterior cortical atrophy.